At a glance
ClinicalIndex Comparison RecordPhase 1Active· 6 enrolled
Drug / intervention
EBV immunological agentbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
In Brief
A Phase 1 clinical trial evaluating EBV immunological agent for Malignant Tumor. Active but no longer recruiting, targeting 6 participants across 1 site.
Detailed Summary
To evaluate the safety of therapeutic immunological agent against EBV-positive advanced malignancies, examining the incidence, type of occurrence, and severity of adverse events in relation to the agent tested, and initially exploring the effectiveness of the immunological agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Tumor
CountriesChina
Collaborators--
Timeline
Phase 1Active
202320242025202620272028
First PostedFeb 2023
Enrollment StartFeb 2023
Primary CompletionApr 2024
TodayJul 2026
Study CompletionDec 2027
First PostedFeb 1, 2023
Enrollment StartFeb 8, 2023
Primary CompletionApr 24, 2024
Study CompletionDec 31, 2027
TodayJul 1, 2026
Enrollment to primary: 1.2 yearsPosted 3.4 years ago
Interventions
EBV immunological agentbiological
2\*10\^7 and 5\*10\^7